VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
16. Oktober 2018 08:00 ET
|
VBI Vaccines, Inc.
Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE...